FibroGen Stock Climbs Following Positive Clinical and Financial Developments

FibroGen shares are trading higher after the company reported promising second-quarter 2025 financial results and provided updates on clinical advancements including FG-3246 and roxadustat, with plans to extend its cash runway into 2028.